Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Deloitte
US Army
Chubb
Dow
AstraZeneca
Fuji
Mallinckrodt
Daiichi Sankyo

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,101,569

« Back to Dashboard

Which drugs does patent 7,101,569 protect, and when does it expire?

Patent 7,101,569 protects LEVOXYL and is included in one NDA.

This patent has twenty-six patent family members in nine countries.
Summary for Patent: 7,101,569
Title:Methods of administering levothyroxine pharmaceutical compositions
Abstract:The present invention generally relates to stable pharmaceutical compositions, and methods of making and administering such compositions. In one aspect, the invention features stabilized pharmaceutical compositions that include pharmaceutically active ingredients such as levothyroxine (T4) sodium and liothyronine (T3) sodium (thyroid hormone drugs), preferably in an immediate release solid dosage form. Also provided are methods for making and using such immediate release and stabilized compositions.
Inventor(s): Franz; G. Andrew (St. Louis, MO), Strauss; Elaine A. (Seminole, FL), DiMenna; Phillip A. (St. Petersburg, FL), Gemma; Rocco L. (Dover, OH)
Assignee:
Application Number:10/218,718
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,101,569

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-001 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-002 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-003 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Sign Up
King Pharms LEVOXYL levothyroxine sodium TABLET;ORAL 021301-004 May 25, 2001 AB1,AB3 RX Yes No ➤ Sign Up ➤ Sign Up METHOD OF USE OF ADMINISTERING LEVOTHYROXINE ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,101,569

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,555,581 Levothyroxine compositions and methods ➤ Sign Up
7,067,148 Stabilized pharmaceutical and thyroid hormone compositions and method of preparation ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Covington
Federal Trade Commission
Citi
Fuji
UBS
Mallinckrodt
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.